Alnylam Pharmaceuticals (ALNY) Competitors $320.53 -4.16 (-1.28%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$319.14 -1.39 (-0.43%) As of 07/18/2025 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALNY vs. AMGN, GILD, VRTX, REGN, BIIB, INCY, UTHR, NBIX, EXEL, and BMRNShould you be buying Alnylam Pharmaceuticals stock or one of its competitors? The main competitors of Alnylam Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL), and BioMarin Pharmaceutical (BMRN). These companies are all part of the "biotechnology" industry. Alnylam Pharmaceuticals vs. Its Competitors Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Biogen Incyte United Therapeutics Neurocrine Biosciences Exelixis BioMarin Pharmaceutical Alnylam Pharmaceuticals (NASDAQ:ALNY) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability. Do institutionals and insiders have more ownership in ALNY or AMGN? 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are owned by insiders. Comparatively, 0.8% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more risk & volatility, ALNY or AMGN? Alnylam Pharmaceuticals has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Does the media favor ALNY or AMGN? In the previous week, Amgen had 26 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 58 mentions for Amgen and 32 mentions for Alnylam Pharmaceuticals. Amgen's average media sentiment score of 1.28 beat Alnylam Pharmaceuticals' score of 0.75 indicating that Amgen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 11 Very Positive mention(s) 5 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Amgen 48 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer ALNY or AMGN? Alnylam Pharmaceuticals presently has a consensus price target of $346.13, suggesting a potential upside of 7.99%. Amgen has a consensus price target of $307.82, suggesting a potential upside of 4.43%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Alnylam Pharmaceuticals is more favorable than Amgen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alnylam Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 21 Buy rating(s) 0 Strong Buy rating(s) 2.80Amgen 2 Sell rating(s) 12 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.35 Is ALNY or AMGN more profitable? Amgen has a net margin of 17.39% compared to Alnylam Pharmaceuticals' net margin of -11.49%. Amgen's return on equity of 176.11% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Alnylam Pharmaceuticals-11.49% -510.31% -6.48% Amgen 17.39%176.11%12.39% Which has stronger earnings & valuation, ALNY or AMGN? Amgen has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlnylam Pharmaceuticals$2.35B17.80-$278.16M-$2.09-153.36Amgen$33.42B4.74$4.09B$10.9626.89 SummaryAmgen beats Alnylam Pharmaceuticals on 11 of the 17 factors compared between the two stocks. Get Alnylam Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALNY vs. The Competition Export to ExcelMetricAlnylam PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$42.34B$2.95B$5.54B$9.40BDividend YieldN/A2.44%3.75%4.03%P/E Ratio-153.3619.7528.0119.79Price / Sales17.80298.31432.5697.34Price / CashN/A42.5936.1658.27Price / Book616.407.678.125.65Net Income-$278.16M-$55.28M$3.25B$257.91M7 Day Performance1.77%4.85%1.64%3.35%1 Month Performance2.63%11.70%7.27%11.09%1 Year Performance34.77%3.69%32.88%18.99% Alnylam Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALNYAlnylam Pharmaceuticals4.1378 of 5 stars$320.53-1.3%$346.13+8.0%+35.4%$42.34B$2.35B-153.362,230News CoverageAnalyst ForecastAnalyst RevisionAMGNAmgen4.4015 of 5 stars$297.03+0.6%$307.82+3.6%-10.9%$159.72B$33.42B27.1028,000Trending NewsAnalyst RevisionGILDGilead Sciences4.9192 of 5 stars$112.09+2.2%$111.38-0.6%+47.2%$139.43B$28.75B23.6017,600Trending NewsInsider TradeAnalyst RevisionVRTXVertex Pharmaceuticals4.7254 of 5 stars$472.35+0.7%$511.71+8.3%-5.8%$121.30B$11.02B-120.506,100Positive NewsAnalyst RevisionREGNRegeneron Pharmaceuticals4.8169 of 5 stars$570.59+0.5%$814.57+42.8%-49.2%$61.60B$14.09B14.5315,106BIIBBiogen4.9154 of 5 stars$133.11-0.8%$188.48+41.6%-44.5%$19.50B$9.68B13.147,605Trending NewsInsider TradeAnalyst RevisionINCYIncyte4.5495 of 5 stars$69.98+2.0%$74.47+6.4%+3.8%$13.55B$4.24B218.692,617Insider TradeAnalyst RevisionUTHRUnited Therapeutics4.9864 of 5 stars$297.68+0.7%$383.08+28.7%-11.2%$13.43B$2.88B11.881,305Positive NewsNBIXNeurocrine Biosciences4.4742 of 5 stars$135.13+1.3%$163.91+21.3%-8.4%$13.37B$2.41B45.811,800Trending NewsAnalyst RevisionEXELExelixis4.8144 of 5 stars$45.58+1.6%$45.22-0.8%+97.1%$12.43B$2.17B20.721,147Analyst ForecastBMRNBioMarin Pharmaceutical4.9887 of 5 stars$58.23+0.2%$93.78+61.1%-31.3%$11.17B$2.85B21.653,040News CoveragePositive NewsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies Amgen Alternatives Gilead Sciences Alternatives Vertex Pharmaceuticals Alternatives Regeneron Pharmaceuticals Alternatives Biogen Alternatives Incyte Alternatives United Therapeutics Alternatives Neurocrine Biosciences Alternatives Exelixis Alternatives BioMarin Pharmaceutical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALNY) was last updated on 7/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
